ReviewBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2015
Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature.
Review in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03907423 (Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Biomarkers to predict or measure steroid resistance in idiopathic nephrotic syndrome: A systematic review.PloS one · 2025Pooled it
- Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial.BMC pharmacology & toxicology · 2025Trial
- Article
- Probing uric acid-related prognostic genes and their molecular mechanisms in prostate cancer based on transcriptomic data.Discover oncology · 2026Article
- Nifedipine Induces FAM20A Upregulation and LRP2/CUBN-Mediated Fetuin-A Accumulation in Gingival Overgrowth.International journal of dentistry · 2026Article
- Temporal Dynamics of the Plasma Proteomic Landscape Reveals Maladaptation in ME/CFS Following Exertion.Molecular & cellular proteomics : MCP · 2025Article
- Fetuin-A and Heme Oxygenase 1 as Potential New Markers in the Diagnosis of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- Molecular Imprints of Clinical Comorbidities in Hypothalamic Extracellular Vesicles at the Onset of Obesity.ACS omega · 2025Article
- The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review.Therapeutic advances in chronic disease · 2025Review
- The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.International journal of molecular sciences · 2024Review
- Exosomal AHSG in ovarian cancer ascites inhibits malignant progression of ovarian cancer by p53/FAK/Src signaling.Translational cancer research · 2024Article
- Rethinking Mitral Annular Calcification and Its Clinical Significance: From Passive Process to Active Pathology.Journal of personalized medicine · 2024Review
- Multiomics Picture of Obesity in Young Adults.Biology · 2024Article
- Molecular insights into the proteomic composition of porcine treated dentin matrix.Materials today. Bio · 2024Article
- AHSG, a Gene Promoting Tumour Proliferation, Migration and Invasion, is an Independent Prognostic Factor for Poor Overall Survival in Lung Adenocarcinoma.Molecular biology reports · 2023Article
- Tissue and plasma proteomic profiling indicates AHSG as a potential biomarker for ascending thoracic aortic aneurysms.BMC cardiovascular disorders · 2023Article
- Serum fetuin-A and RANKL levels in patients with early stage breast cancer.Journal of medical biochemistry · 2023Article
- Article
- PFOA-Induced Ovotoxicity Differs Between Lean and Obese Mice With Impacts on Ovarian Reproductive and DNA Damage Sensing and Repair Proteins.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Alpha-2-Heremans-Schmid-glycoprotein (AHSG) a potential biomarker associated with prognosis of chromophobe renal cell carcinoma: The PROPOLIS study.Health science reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFetuin-A, also called Alpha 2-Heremans Schmid Glycoprotein, is a multifunctional plasma agent what has been proven in animal and human studies. It plays a role as a physiological inhibitor of insulin receptor tyrosine kinase associated with insulin resistance and a negative acute phase reactant. It also regulates bone remodeling and calcium metabolism being an important inhibitor of calcium salt precipitation and vascular calcifications.
methodsPubMed database was searched for articles from 2002 up to December 2014 to identify the role of fetuin-A in the pathogenesis of selected internal diseases.
resultsDue to secretion of fetuin-A mainly by the liver, it may be a marker of liver function and predictor of mortality in patients with cirrhosis and hepatocellular cancer. The associations between high fetuin-A and metabolic syndrome as well as its hepatic manifestation- nonalcoholic fatty liver disease and atherogenic lipid profile have been well proven. However, fetuin-A relation with BMI is not so clear. Contrary to few reports, many authors suggest that fetuin-A may be an independent risk factor for type 2 diabetes and marker of diabetic complications. Close associations of high and low fetuin-A concentrations with cardiovascular diseases and mortality risk have been reported which is explained by differences in analyzed populations, stages of atherosclerosis and calcifications, coexistence of type 2 diabetes or kidney dysfunction and different main pathways of fetuin-A actions in various diseases.
conclusionsFetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.